Black Diamond Therapeutics annual free cash flow
2018
2019
2020
2021
2022
2023
2024
Black Diamond Therapeutics Free Cash Flow (FCF) History (BDTX)
Black Diamond Therapeutics reported −$62.3M in free cash flow for fiscal 2024, an increase of $4.4M from the previous fiscal year.
View full Black Diamond Therapeutics company overviewBlack Diamond Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-12-31 | −$62.3M | $4.4M | — | — |
| 2023 | 2023-12-31 | −$66.8M | $18.5M | — | — |
| 2022 | 2022-12-31 | −$85.3M | $17.6M | — | — |
| 2021 | 2021-12-31 | −$102.9M | −$50.6M | — | — |
| 2020 | 2020-12-31 | −$52.3M | −$27.6M | — | — |
| 2019 | 2019-12-31 | −$24.7M | −$16.2M | — | — |
| 2018 | 2018-12-31 | −$8.5M | — | — | — |
Black Diamond Therapeutics quarterly free cash flow
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2023 | 2023-12-31 | −$14.0M | $8.0M | — | — |
| Q3 2023 | 2023-09-30 | −$18.4M | −$1.9M | — | — |
| Q2 2023 | 2023-06-30 | −$14.4M | $3.9M | — | — |
| Q1 2023 | 2023-03-31 | −$20.0M | $8.6M | — | — |
| Q4 2022 | 2022-12-31 | −$21.9M | $2.4M | — | — |
| Q3 2022 | 2022-09-30 | −$16.5M | $11.5M | — | — |
| Q2 2022 | 2022-06-30 | −$18.3M | $7.8M | — | — |
| Q1 2022 | 2022-03-31 | −$28.6M | −$4.1M | — | — |
| Q4 2021 | 2021-12-31 | −$24.4M | −$8.5M | — | — |
| Q3 2021 | 2021-09-30 | −$28.0M | −$16.5M | — | — |
| Q2 2021 | 2021-06-30 | −$26.0M | −$12.4M | — | — |
| Q1 2021 | 2021-03-31 | −$24.5M | −$13.2M | — | — |
| Q4 2020 | 2020-12-31 | −$15.9M | −$8.4M | — | — |
| Q3 2020 | 2020-09-30 | −$11.5M | −$6.2M | — | — |
| Q2 2020 | 2020-06-30 | −$13.6M | −$8.6M | — | — |
| Q1 2020 | 2020-03-31 | −$11.3M | −$4.4M | — | — |
| Q4 2019 | 2019-12-31 | −$7.5M | — | — | — |
| Q3 2019 | 2019-09-30 | −$5.3M | — | — | — |
| Q2 2019 | 2019-06-30 | −$5.0M | — | — | — |
| Q1 2019 | 2019-03-31 | −$6.9M | — | — | — |
Black Diamond Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$24.7M to −$62.3M, a net decrease of $37.6M. Black Diamond Therapeutics's latest reported quarter, Q4 2023, generated −$14.0M in free cash flow, an increase of $8.0M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Black Diamond Therapeutics filings at SEC.gov ↗